Compare BMRC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMRC | ASMB |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.6M | 440.0M |
| IPO Year | 2007 | 2010 |
| Metric | BMRC | ASMB |
|---|---|---|
| Price | $23.97 | $28.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $28.00 | ★ $43.40 |
| AVG Volume (30 Days) | 81.8K | ★ 92.6K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $330.53 | $33.33 |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | $100.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.14 | $7.76 |
| 52 Week High | $28.48 | $39.71 |
| Indicator | BMRC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 48.18 |
| Support Level | $21.08 | $26.50 |
| Resistance Level | $24.26 | $30.66 |
| Average True Range (ATR) | 1.04 | 1.46 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 13.42 | 36.74 |
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.